An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Illumina Named to the Dow Jones Sustainability Indices for the Fifth Consecutive Year
Rhea-AI Impact
(No impact)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Illumina (ILMN) has been named to the Dow Jones Sustainability World Index and the North America Index for 2023 in the Life Sciences Tools & Services Industry. This is the fifth consecutive year the company has been named to the prestigious list and the fourth year that it has led with the highest score in the Life Sciences Tools & Services Sector industry in North America. The Dow Jones Sustainability Index (DJSI) is based on the S&P Global Corporate Sustainability Assessment (CSA) annual evaluation of companies' sustainability practices. The DJSI represents the top 10% of each industry in the DJSI World Index and the top 20% for the DJSI North America Index. Illumina's commitment to deepening its impact on human health and sustainability is evident through this recognition.
Positive
None.
Negative
None.
NORTHAMPTON, MA / ACCESSWIRE / December 12, 2023 / Illumina has been named to the Dow Jones Sustainability World Index and the North America Index for 2023 in the Life Sciences Tools & Services Industry. This is the fifth consecutive year the company has been named to the prestigious list and the fourth year that it has led with the highest score in the Life Sciences Tools & Services Sector industry in North America.
The Dow Jones Sustainability Index (DJSI) is based on the S&P Global Corporate Sustainability Assessment (CSA) annual evaluation of companies' sustainability practices. The DJSI represents the top 10% of each industry in the DJSI World Index and the top 20% for the DJSI North America Index.
At Illumina, we are driven by the power of genomics to positively impact the world and shape a more sustainable and equitable future for all. This recognition demonstrates our commitment to deepen our impact on human health by serving as a champion for patients, our communities, our people, and our planet.Learn more about our impact and sustainability practices here.
About Illumina
Illumina is improving human health by unlocking the power of the genome. In 2023 we celebrate 25 years of innovation, which has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Illumina has been named to the Dow Jones Sustainability World Index and the North America Index for 2023 in the Life Sciences Tools & Services Industry. This is the fifth consecutive year the company has been named to the prestigious list and the fourth year that it has led with the highest score in the Life Sciences Tools & Services Sector industry in North America.
The DJSI is based on the S&P Global Corporate Sustainability Assessment (CSA) annual evaluation of companies' sustainability practices. It represents the top 10% of each industry in the DJSI World Index and the top 20% for the DJSI North America Index.
Illumina's recognition demonstrates the company's commitment to deepening its impact on human health by serving as a champion for patients, communities, people, and the planet.
at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
